Savara(US:SVRA) Globenewswire·2025-09-29 20:09Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements about the company's drug application process for MOLBREEVI BLA [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [3]. - Specific allegations include a lack of sufficient information about MOLBREEVI's chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [3]. - The delay in regulatory approval raised concerns that Savara would need to raise additional capital, contradicting the company's public statements [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for the shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].